Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. / Møller-Bisgaard, Signe; Georgiadis, Stylianos; Hørslev-Petersen, Kim; Ejbjerg, Bo; Hetland, Merete Lund; Ørnbjerg, Lykke Midtbøll; Glinatsi, Daniel; Møller, Jakob; Boesen, Mikael; Stengaard-Pedersen, Kristian; Madsen, Ole Rintek; Jensen, Bente; Villadsen, Jan Alexander; Hauge, Ellen Margrethe; Bennett, Philip; Hendricks, Oliver; Asmussen, Karsten; Kowalski, Marcin; Lindegaard, Hanne; Bliddal, Henning; Krogh, Niels Steen; Ellingsen, Torkell; Nielsen, Agnete H.; Balding, Lone; Jurik, Anne Grethe; Thomsen, Henrik S.; Østergaard, Mikkel.

I: Rheumatology, Bind 60, Nr. 1, 2021, s. 380-391.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Møller-Bisgaard, S, Georgiadis, S, Hørslev-Petersen, K, Ejbjerg, B, Hetland, ML, Ørnbjerg, LM, Glinatsi, D, Møller, J, Boesen, M, Stengaard-Pedersen, K, Madsen, OR, Jensen, B, Villadsen, JA, Hauge, EM, Bennett, P, Hendricks, O, Asmussen, K, Kowalski, M, Lindegaard, H, Bliddal, H, Krogh, NS, Ellingsen, T, Nielsen, AH, Balding, L, Jurik, AG, Thomsen, HS & Østergaard, M 2021, 'Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission', Rheumatology, bind 60, nr. 1, s. 380-391. https://doi.org/10.1093/rheumatology/keaa496

APA

Møller-Bisgaard, S., Georgiadis, S., Hørslev-Petersen, K., Ejbjerg, B., Hetland, M. L., Ørnbjerg, L. M., Glinatsi, D., Møller, J., Boesen, M., Stengaard-Pedersen, K., Madsen, O. R., Jensen, B., Villadsen, J. A., Hauge, E. M., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M., Lindegaard, H., ... Østergaard, M. (2021). Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology, 60(1), 380-391. https://doi.org/10.1093/rheumatology/keaa496

Vancouver

Møller-Bisgaard S, Georgiadis S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Ørnbjerg LM o.a. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology. 2021;60(1):380-391. https://doi.org/10.1093/rheumatology/keaa496

Author

Møller-Bisgaard, Signe ; Georgiadis, Stylianos ; Hørslev-Petersen, Kim ; Ejbjerg, Bo ; Hetland, Merete Lund ; Ørnbjerg, Lykke Midtbøll ; Glinatsi, Daniel ; Møller, Jakob ; Boesen, Mikael ; Stengaard-Pedersen, Kristian ; Madsen, Ole Rintek ; Jensen, Bente ; Villadsen, Jan Alexander ; Hauge, Ellen Margrethe ; Bennett, Philip ; Hendricks, Oliver ; Asmussen, Karsten ; Kowalski, Marcin ; Lindegaard, Hanne ; Bliddal, Henning ; Krogh, Niels Steen ; Ellingsen, Torkell ; Nielsen, Agnete H. ; Balding, Lone ; Jurik, Anne Grethe ; Thomsen, Henrik S. ; Østergaard, Mikkel. / Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. I: Rheumatology. 2021 ; Bind 60, Nr. 1. s. 380-391.

Bibtex

@article{c305b7d2ed7a4a659595c5dd8cf084e4,
title = "Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission",
abstract = "OBJECTIVES: To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy. METHODS: RA patients (DAS28-CRP <3.2, no swollen joints) receiving conventional synthetic DMARDs were randomized to conventional or MRI-targeted treat-to-target strategies with predefined algorithmic treatment escalations. Potentially predictive baseline variables were tested in multivariate logistic regression analyses. RESULTS: In the 171 patients included, baseline MRI osteitis independently predicted progression in MRI erosion [odds ratio (OR) 1.13 (95% CI 1.06, 1.22)], joint space narrowing [OR 1.15 (95% CI 1.07, 1.24)] and combined damage [OR 1.23 (95% CI 1.13, 1.37)], while tenosynovitis independently predicted MRI erosion progression [OR 1.13 (95% CI 1.03, 1.25)]. A predictor of radiographic erosion progression was age, while gender predicted progression in joint space narrowing. Following an MRI treat-to-target strategy predicted stringent remission across all remission definitions: Clinical Disease Activity Index remission OR 2.94 (95% CI 1.25, 7.52), Simplified Disease Activity Index remission OR 2.50 (95% CI 1.01, 6.66), ACR/EULAR Boolean remission OR 5.47 (95% CI 2.33, 14.13). Similarly, low tender joint count and low patient visual analogue scale pain and global independently predicted achievement of more stringent remission. CONCLUSION: Baseline MRI osteitis and tenosynovitis were independent predictors of 2 year MRI damage progression in RA patients in clinical remission, while independent predictors of radiographic damage progression were age and gender. Following an MRI treat-to-target strategy, low scores of patient-reported outcomes and low tender joint count predicted achievement of stringent remission. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01656278.",
keywords = "disease activity, joint damage progression, MRI, outcome research, predictors, remission, rheumatoid arthritis, treat-to-target",
author = "Signe M{\o}ller-Bisgaard and Stylianos Georgiadis and Kim H{\o}rslev-Petersen and Bo Ejbjerg and Hetland, {Merete Lund} and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Daniel Glinatsi and Jakob M{\o}ller and Mikael Boesen and Kristian Stengaard-Pedersen and Madsen, {Ole Rintek} and Bente Jensen and Villadsen, {Jan Alexander} and Hauge, {Ellen Margrethe} and Philip Bennett and Oliver Hendricks and Karsten Asmussen and Marcin Kowalski and Hanne Lindegaard and Henning Bliddal and Krogh, {Niels Steen} and Torkell Ellingsen and Nielsen, {Agnete H.} and Lone Balding and Jurik, {Anne Grethe} and Thomsen, {Henrik S.} and Mikkel {\O}stergaard",
year = "2021",
doi = "10.1093/rheumatology/keaa496",
language = "English",
volume = "60",
pages = "380--391",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission

AU - Møller-Bisgaard, Signe

AU - Georgiadis, Stylianos

AU - Hørslev-Petersen, Kim

AU - Ejbjerg, Bo

AU - Hetland, Merete Lund

AU - Ørnbjerg, Lykke Midtbøll

AU - Glinatsi, Daniel

AU - Møller, Jakob

AU - Boesen, Mikael

AU - Stengaard-Pedersen, Kristian

AU - Madsen, Ole Rintek

AU - Jensen, Bente

AU - Villadsen, Jan Alexander

AU - Hauge, Ellen Margrethe

AU - Bennett, Philip

AU - Hendricks, Oliver

AU - Asmussen, Karsten

AU - Kowalski, Marcin

AU - Lindegaard, Hanne

AU - Bliddal, Henning

AU - Krogh, Niels Steen

AU - Ellingsen, Torkell

AU - Nielsen, Agnete H.

AU - Balding, Lone

AU - Jurik, Anne Grethe

AU - Thomsen, Henrik S.

AU - Østergaard, Mikkel

PY - 2021

Y1 - 2021

N2 - OBJECTIVES: To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy. METHODS: RA patients (DAS28-CRP <3.2, no swollen joints) receiving conventional synthetic DMARDs were randomized to conventional or MRI-targeted treat-to-target strategies with predefined algorithmic treatment escalations. Potentially predictive baseline variables were tested in multivariate logistic regression analyses. RESULTS: In the 171 patients included, baseline MRI osteitis independently predicted progression in MRI erosion [odds ratio (OR) 1.13 (95% CI 1.06, 1.22)], joint space narrowing [OR 1.15 (95% CI 1.07, 1.24)] and combined damage [OR 1.23 (95% CI 1.13, 1.37)], while tenosynovitis independently predicted MRI erosion progression [OR 1.13 (95% CI 1.03, 1.25)]. A predictor of radiographic erosion progression was age, while gender predicted progression in joint space narrowing. Following an MRI treat-to-target strategy predicted stringent remission across all remission definitions: Clinical Disease Activity Index remission OR 2.94 (95% CI 1.25, 7.52), Simplified Disease Activity Index remission OR 2.50 (95% CI 1.01, 6.66), ACR/EULAR Boolean remission OR 5.47 (95% CI 2.33, 14.13). Similarly, low tender joint count and low patient visual analogue scale pain and global independently predicted achievement of more stringent remission. CONCLUSION: Baseline MRI osteitis and tenosynovitis were independent predictors of 2 year MRI damage progression in RA patients in clinical remission, while independent predictors of radiographic damage progression were age and gender. Following an MRI treat-to-target strategy, low scores of patient-reported outcomes and low tender joint count predicted achievement of stringent remission. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01656278.

AB - OBJECTIVES: To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy. METHODS: RA patients (DAS28-CRP <3.2, no swollen joints) receiving conventional synthetic DMARDs were randomized to conventional or MRI-targeted treat-to-target strategies with predefined algorithmic treatment escalations. Potentially predictive baseline variables were tested in multivariate logistic regression analyses. RESULTS: In the 171 patients included, baseline MRI osteitis independently predicted progression in MRI erosion [odds ratio (OR) 1.13 (95% CI 1.06, 1.22)], joint space narrowing [OR 1.15 (95% CI 1.07, 1.24)] and combined damage [OR 1.23 (95% CI 1.13, 1.37)], while tenosynovitis independently predicted MRI erosion progression [OR 1.13 (95% CI 1.03, 1.25)]. A predictor of radiographic erosion progression was age, while gender predicted progression in joint space narrowing. Following an MRI treat-to-target strategy predicted stringent remission across all remission definitions: Clinical Disease Activity Index remission OR 2.94 (95% CI 1.25, 7.52), Simplified Disease Activity Index remission OR 2.50 (95% CI 1.01, 6.66), ACR/EULAR Boolean remission OR 5.47 (95% CI 2.33, 14.13). Similarly, low tender joint count and low patient visual analogue scale pain and global independently predicted achievement of more stringent remission. CONCLUSION: Baseline MRI osteitis and tenosynovitis were independent predictors of 2 year MRI damage progression in RA patients in clinical remission, while independent predictors of radiographic damage progression were age and gender. Following an MRI treat-to-target strategy, low scores of patient-reported outcomes and low tender joint count predicted achievement of stringent remission. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01656278.

KW - disease activity

KW - joint damage progression

KW - MRI

KW - outcome research

KW - predictors

KW - remission

KW - rheumatoid arthritis

KW - treat-to-target

U2 - 10.1093/rheumatology/keaa496

DO - 10.1093/rheumatology/keaa496

M3 - Journal article

C2 - 32929463

AN - SCOPUS:85099428399

VL - 60

SP - 380

EP - 391

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 1

ER -

ID: 255684780